Abstract 153P
Background
Long non-coding RNAs (LncRNAs) widely involved in various processes in cancers. Exosomes are important elements in tumor microenvironment, and usually transmit miRNAs or LncRNAs in cancer cells. Rapid progression of residual hepatocellular carcinoma after insufficient radiofrequency ablation has been confirmed, however, the role of exosomes in the underlying mechanism has never been unmasked.
Methods
The expression of LINC00174 was modified in the Huh7 and Huh7-H cell lines respectively. Western blot was used to examine the level of the exosomal protein marker. Transwell assay and western blot were used to evaluate the migration function of the HCC cells. qRT-PCR and western blot were used to examine the expression of LINC00174 level in the exosomes derived from the modified HCC cells. Online UCSC and JASPAR were used to predict the LINC00174 transcription. ChIP and a luciferase reporter assay were used to validate the positive regulation of MYC on LINC00174 transcription.
Results
LINC00174 was upregulated in both the cells and exosomes of cells. LINC00174 affected HCC cell migration and EMT via ERK and JNK pathways. The changes of c-JUN and p-c-JUN level in HCC cells treated with exosomes containing different level of LINC00174. JASPAR revealed the binding motif of c-JUN protein on the promoter region of its targets. ChIP and luciferase reporter assay validated that c-JUN was a positive regulator of MYCBP transcription. Exosomal LINC00174 activated Ras-regulated ERK and JNK pathways to enhance c-JUN expression and phosphorylation, and therefore upregulated MYCBP to strengthen MYC transcriptional activity, finally resulting in accelerated HCC progression.
Conclusions
Exosomal LINC00174 facilitates EMT via ERK-JNK/c-JUN/MYCBP/c-MYC signaling, providing a new way for the HCC patients unfortunately received the insufficient RFA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhe jiang Cancer Hospital.
Funding
National Natural Science Funds of China (Grant number: 81702371).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract